{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:15:29Z","timestamp":1794856529285,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Endothelial cells play a key role in the regulation of disease. Defective regulation of endothelial cell homeostasis may cause mesenchymal activation of other endothelial cells or neighboring cell types, and in both cases contributes to organ fibrosis. Regulatory control of endothelial cell homeostasis is not well studied. Diabetes accelerates renal fibrosis in mice lacking the endothelial glucocorticoid receptor (GR), compared to control mice. Hypercholesterolemia further enhances severe renal fibrosis. The fibrogenic phenotype in the kidneys of diabetic mice lacking endothelial GR is associated with aberrant cytokine and chemokine reprogramming, augmented Wnt signaling and suppression of fatty acid oxidation. Both neutralization of IL-6 and Wnt inhibition improve kidney fibrosis by mitigating mesenchymal transition. Conditioned media from endothelial cells from diabetic mice lacking endothelial GR stimulate Wnt signaling-dependent epithelial-to-mesenchymal transition in tubular epithelial cells from diabetic controls. These data demonstrate that endothelial GR is an essential antifibrotic molecule in diabetes.<\/jats:p>","DOI":"10.1038\/s41467-021-22617-y","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T06:16:55Z","timestamp":1619072215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy"],"prefix":"10.1038","volume":"12","author":[{"given":"Swayam Prakash","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocean","family":"Setia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-502X","authenticated-orcid":false,"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-1539","authenticated-orcid":false,"given":"Daisuke","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-7367","authenticated-orcid":false,"given":"Alan","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-1924","authenticated-orcid":false,"given":"Carlos","family":"Fernandez-Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-8695","authenticated-orcid":false,"given":"Julie","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"22617_CR1","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy, K., Kang, H. M., Hostetter, T. & Susztak, K. Molecular mechanisms of diabetic kidney disease. J. Clin. Investig. 124, 2333\u20132340 (2014).","journal-title":"J. Clin. Investig."},{"key":"22617_CR2","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1053\/j.ajkd.2013.10.047","volume":"63","author":"SS Badal","year":"2014","unstructured":"Badal, S. S. & Danesh, F. R. New insights into molecular mechanisms of diabetic kidney disease. Am. J. Kidney Dis. 63, S63\u2013S83 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"22617_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nrd.2016.67","volume":"15","author":"MD Breyer","year":"2016","unstructured":"Breyer, M. D. & Susztak, K. The next generation of therapeutics for chronic kidney disease. Nat. Rev. Drug Discov. 15, 568\u2013588 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"22617_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","volume":"176","author":"BD Humphreys","year":"2010","unstructured":"Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85\u201397 (2010).","journal-title":"Am. J. Pathol."},{"key":"22617_CR5","doi-asserted-by":"publisher","unstructured":"Kuppe, C. et al. Decoding myofibroblast origins in human kidney fibrosis. Nature https:\/\/doi.org\/10.1038\/s41586-020-2941-1 (2020).","DOI":"10.1038\/s41586-020-2941-1"},{"key":"22617_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047\u20131053 (2013).","journal-title":"Nat. Med."},{"key":"22617_CR7","doi-asserted-by":"publisher","first-page":"125469","DOI":"10.1155\/2013\/125469","volume":"2013","author":"SP Srivastava","year":"2013","unstructured":"Srivastava, S. P., Koya, D. & Kanasaki, K. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. Biomed. Res. Int. 2013, 125469 (2013).","journal-title":"Biomed. Res. Int."},{"key":"22617_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2019.00904","volume":"10","author":"SP Srivastava","year":"2019","unstructured":"Srivastava, S. P., Hedayat, F. A., Kanasaki, K. & Goodwin, J. E. microRNA crosstalk influences epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney. Front. Pharm. 10, 904 (2019).","journal-title":"Front. Pharm."},{"key":"22617_CR9","doi-asserted-by":"crossref","first-page":"6962801","DOI":"10.1155\/2016\/6962801","volume":"2016","author":"D Medici","year":"2016","unstructured":"Medici, D. Endothelial-mesenchymal transition in regenerative medicine. Stem Cells Int. 2016, 6962801 (2016).","journal-title":"Stem Cells Int."},{"key":"22617_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1152\/physrev.00001.2017","volume":"98","author":"G Eelen","year":"2018","unstructured":"Eelen, G. et al. Endothelial cell metabolism. Physiol. Rev. 98, 3\u201358 (2018).","journal-title":"Physiol. Rev."},{"key":"22617_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fcell.2018.00082","volume":"6","author":"K Theodorou","year":"2018","unstructured":"Theodorou, K. & Boon, R. A. Endothelial cell metabolism in atherosclerosis. Front. Cell Dev. Biol. 6, 82 (2018).","journal-title":"Front. Cell Dev. Biol."},{"key":"22617_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-018-0749-z","volume":"565","author":"HL Zhou","year":"2019","unstructured":"Zhou, H. L. et al. Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. Nature 565, 96\u2013100 (2019).","journal-title":"Nature"},{"key":"22617_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","volume":"30","author":"AR Cantelmo","year":"2016","unstructured":"Cantelmo, A. R. et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 30, 968\u2013985 (2016).","journal-title":"Cancer Cell"},{"key":"22617_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12240","volume":"7","author":"B Cruys","year":"2016","unstructured":"Cruys, B. et al. Glycolytic regulation of cell rearrangement in angiogenesis. Nat. Commun. 7, 12240 (2016).","journal-title":"Nat. Commun."},{"key":"22617_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature14362","volume":"520","author":"S Schoors","year":"2015","unstructured":"Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"22617_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2018.01.010","volume":"69","author":"J Xiong","year":"2018","unstructured":"Xiong, J. et al. A metabolic basis for endothelial-to-mesenchymal transition. Mol. Cell 69, 689\u2013698 (2018).","journal-title":"Mol. Cell"},{"key":"22617_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.molmed.2018.03.003","volume":"24","author":"S Lovisa","year":"2018","unstructured":"Lovisa, S. & Kalluri, R. Fatty acid oxidation regulates the activation of endothelial-to-mesenchymal transition. Trends Mol. Med. 24, 432\u2013434 (2018).","journal-title":"Trends Mol. Med."},{"key":"22617_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1681\/ASN.2010080793","volume":"21","author":"M Zeisberg","year":"2010","unstructured":"Zeisberg, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrolo. 21, 1819\u20131834 (2010).","journal-title":"J. Am. Soc. Nephrolo."},{"key":"22617_CR19","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1681\/ASN.2008050513","volume":"19","author":"EM Zeisberg","year":"2008","unstructured":"Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282\u20132287 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22617_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952\u2013961 (2007).","journal-title":"Nat. Med."},{"key":"22617_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1161\/HYPERTENSIONAHA.120.15587","volume":"76","author":"J Li","year":"2020","unstructured":"Li, J. et al. Endothelial FGFR1 (fibroblast growth factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of diabetic mice. Hypertension 76, 1935\u20131944 (2020).","journal-title":"Hypertension"},{"key":"22617_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.semcancer.2012.04.004","volume":"22","author":"D Medici","year":"2012","unstructured":"Medici, D. & Kalluri, R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin. Cancer Biol. 22, 379\u2013384 (2012).","journal-title":"Semin. Cancer Biol."},{"key":"22617_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1073\/pnas.1210200110","volume":"110","author":"JE Goodwin","year":"2013","unstructured":"Goodwin, J. E., Feng, Y., Velazquez, H. & Sessa, W. C. Endothelial glucocorticoid receptor is required for protection against sepsis. Proc. Natl Acad. Sci. USA 110, 306\u2013311 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22617_CR24","doi-asserted-by":"publisher","first-page":"e108126","DOI":"10.1371\/journal.pone.0108126","volume":"9","author":"JE Goodwin","year":"2014","unstructured":"Goodwin, J. E., Feng, Y., Velazquez, H., Zhou, H. & Sessa, W. C. Loss of the endothelial glucocorticoid receptor prevents the therapeutic protection afforded by dexamethasone after LPS. PLoS ONE 9, e108126 (2014).","journal-title":"PLoS ONE"},{"key":"22617_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/ATVBAHA.114.304525","volume":"35","author":"JE Goodwin","year":"2015","unstructured":"Goodwin, J. E. et al. Endothelial glucocorticoid receptor suppresses atherogenesis\u2013brief report. Arterioscler. Thromb. Vasc. Biol. 35, 779\u2013782 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"22617_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10490-z","volume":"7","author":"H Zhou","year":"2017","unstructured":"Zhou, H. et al. Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury. Sci. Rep. 7, 9833 (2017).","journal-title":"Sci. Rep."},{"key":"22617_CR27","doi-asserted-by":"publisher","unstructured":"Zhou, H. et al. Endothelial cell\u2013glucocorticoid receptor interactions and regulation of Wnt signaling. JCI Insight 5 https:\/\/doi.org\/10.1172\/jci.insight.131384 (2020).","DOI":"10.1172\/jci.insight.131384"},{"key":"22617_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1681\/ASN.2008060566","volume":"20","author":"W He","year":"2009","unstructured":"He, W. et al. Wnt\/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765\u2013776 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22617_CR29","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.2337\/db13-1029","volume":"63","author":"K Kanasaki","year":"2014","unstructured":"Kanasaki, K. et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63, 2120\u20132131 (2014).","journal-title":"Diabetes"},{"key":"22617_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep29884","volume":"6","author":"SP Srivastava","year":"2016","unstructured":"Srivastava, S. P. et al. Effect of antifibrotic MicroRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis. Sci. Rep. 6, 29884 (2016).","journal-title":"Sci. Rep."},{"key":"22617_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/ki.2015.103","volume":"88","author":"S Shi","year":"2015","unstructured":"Shi, S. et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int. 88, 479\u2013489 (2015).","journal-title":"Kidney Int."},{"key":"22617_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1057-0","volume":"9","author":"SP Srivastava","year":"2018","unstructured":"Srivastava, S. P. et al. SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis. Cell Death Dis. 9, 997 (2018).","journal-title":"Cell Death Dis."},{"key":"22617_CR33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2337\/db06-1226","volume":"56","author":"H Sugimoto","year":"2007","unstructured":"Sugimoto, H., Grahovac, G., Zeisberg, M. & Kalluri, R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825\u20131833 (2007).","journal-title":"Diabetes"},{"key":"22617_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40\u201350 (2014).","journal-title":"Immunity"},{"key":"22617_CR35","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00198-014-2720-7","volume":"25","author":"EM Apalset","year":"2014","unstructured":"Apalset, E. M. et al. Interferon gamma (IFN-gamma)-mediated inflammation and the kynurenine pathway in relation to risk of hip fractures: the Hordaland Health Study. Osteoporos. Int. 25, 2067\u20132075 (2014).","journal-title":"Osteoporos. Int."},{"key":"22617_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/1354750X.2018.1501761","volume":"24","author":"SA Fathy","year":"2019","unstructured":"Fathy, S. A., Mohamed, M. R., Ali, M. A. M., El-Helaly, A. E. & Alattar, A. T. Influence of IL-6, IL-10, IFN-gamma and TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers 24, 43\u201355 (2019).","journal-title":"Biomarkers"},{"key":"22617_CR37","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.21037\/tau.2018.11.03","volume":"8","author":"EP Owens","year":"2019","unstructured":"Owens, E. P. et al. Biomarkers and the role of mast cells as facilitators of inflammation and fibrosis in chronic kidney disease. Transl. Androl. Urol. 8, S175\u2013S183 (2019).","journal-title":"Transl. Androl. Urol."},{"key":"22617_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11892-018-0984-6","volume":"18","author":"FB Hickey","year":"2018","unstructured":"Hickey, F. B. & Martin, F. Role of the immune system in diabetic kidney disease. Curr. Diab. Rep. 18, 20 (2018).","journal-title":"Curr. Diab. Rep."},{"key":"22617_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-6393-5_12","volume":"1481","author":"LS Zhang","year":"2016","unstructured":"Zhang, L. S. & Lum, L. Delivery of the porcupine inhibitor WNT974 in mice. Methods Mol. Biol. 1481, 111\u2013117 (2016).","journal-title":"Methods Mol. Biol."},{"key":"22617_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37\u201346 (2015).","journal-title":"Nat. Med."},{"key":"22617_CR41","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.3902","volume":"21","author":"S Lovisa","year":"2015","unstructured":"Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998\u20131009 (2015).","journal-title":"Nat. Med."},{"key":"22617_CR42","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature17184","volume":"531","author":"MT Tran","year":"2016","unstructured":"Tran, M. T. et al. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528\u2013532 (2016).","journal-title":"Nature"},{"key":"22617_CR43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nm.4328","volume":"23","author":"W Qi","year":"2017","unstructured":"Qi, W. et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat. Med. 23, 753\u2013762 (2017).","journal-title":"Nat. Med."},{"key":"22617_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1076\/apab.109.4.377.4237","volume":"109","author":"M Delgado","year":"2001","unstructured":"Delgado, M. & Ganea, D. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch. Physiol. Biochem. 109, 377\u2013382 (2001).","journal-title":"Arch. Physiol. Biochem."},{"key":"22617_CR45","doi-asserted-by":"publisher","first-page":"26003","DOI":"10.1074\/jbc.M111.223164","volume":"286","author":"H Kato","year":"2011","unstructured":"Kato, H. et al. Wnt\/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J. Biol. Chem. 286, 26003\u201326015 (2011).","journal-title":"J. Biol. Chem."},{"key":"22617_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.74","volume":"8","author":"Z Zhou","year":"2017","unstructured":"Zhou, Z. et al. MicroRNA-27a promotes podocyte injury via PPARgamma-mediated beta-catenin activation in diabetic nephropathy. Cell Death Dis. 8, e2658 (2017).","journal-title":"Cell Death Dis."},{"key":"22617_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000488984","volume":"4","author":"Y Feng","year":"2018","unstructured":"Feng, Y., Liang, Y., Ren, J. & Dai, C. Canonical Wnt signaling promotes macrophage proliferation during kidney fibrosis. Kidney Dis. 4, 95\u2013103 (2018).","journal-title":"Kidney Dis."},{"key":"22617_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.jrn.2006.10.012","volume":"17","author":"C Wanner","year":"2007","unstructured":"Wanner, C., Drechsler, C. & Krane, V. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk. J. Ren. Nutr. 17, 75\u201378 (2007).","journal-title":"J. Ren. Nutr."},{"key":"22617_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1755-1536-7-12","volume":"7","author":"SP Srivastava","year":"2014","unstructured":"Srivastava, S. P., Shi, S., Koya, D. & Kanasaki, K. Lipid mediators in diabetic nephropathy. Fibrogenesis Tissue Repair 7, 12 (2014).","journal-title":"Fibrogenesis Tissue Repair"},{"key":"22617_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1194\/jlr.P040501","volume":"55","author":"M Herman-Edelstein","year":"2014","unstructured":"Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M. & Gafter, U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561\u2013572 (2014).","journal-title":"J. Lipid Res."},{"key":"22617_CR51","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00375.2015","volume":"310","author":"P Wahl","year":"2016","unstructured":"Wahl, P., Ducasa, G. M. & Fornoni, A. Systemic and renal lipids in kidney disease development and progression. Am. J. Physiol. Renal. Physiol. 310, F433\u2013F445 (2016).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"22617_CR52","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1681\/ASN.2006060674","volume":"18","author":"CP Kovesdy","year":"2007","unstructured":"Kovesdy, C. P., Anderson, J. E. & Kalantar-Zadeh, K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J. Am. Soc. Nephrol. 18, 304\u2013311 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22617_CR53","first-page":"S29","volume":"31","author":"JR Diamond","year":"1991","unstructured":"Diamond, J. R. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int. Suppl. 31, S29\u2013S34 (1991).","journal-title":"Kidney Int. Suppl."},{"key":"22617_CR54","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1681\/ASN.2006091006","volume":"18","author":"BC Kwan","year":"2007","unstructured":"Kwan, B. C., Kronenberg, F., Beddhu, S. & Cheung, A. K. Lipoprotein metabolism and lipid management in chronic kidney disease. J. Am. Soc. Nephrol. 18, 1246\u20131261 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22617_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","volume":"45","author":"C Baigent","year":"2005","unstructured":"Baigent, C. et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am. J. Kidney Dis. 45, 473\u2013484 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"22617_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","volume":"160","author":"Sharp Collaborative Group.","year":"2010","unstructured":"Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785\u2013794 (2010).","journal-title":"Am. Heart J."},{"key":"22617_CR57","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1463-1326.2012.01566.x","volume":"14","author":"S Kimura","year":"2012","unstructured":"Kimura, S. et al. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes. Metab. 14, 666\u2013669 (2012).","journal-title":"Diabetes Obes. Metab."},{"key":"22617_CR58","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.5551\/jat.9084","volume":"18","author":"M Abe","year":"2011","unstructured":"Abe, M. et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J. Atheroscler. Thromb. 18, 1018\u20131028 (2011).","journal-title":"J. Atheroscler. Thromb."},{"key":"22617_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1464-5491.2010.03139.x","volume":"28","author":"MK Rutter","year":"2011","unstructured":"Rutter, M. K. et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet. Med. 28, 100\u2013108 (2011).","journal-title":"Diabet. Med."},{"key":"22617_CR60","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","volume":"54","author":"HM Colhoun","year":"2009","unstructured":"Colhoun, H. M. et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am. J. Kidney Dis. 54, 810\u2013819 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"22617_CR61","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2337\/diacare.16.10.1376","volume":"16","author":"BA Coonrod","year":"1993","unstructured":"Coonrod, B. A. et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16, 1376\u20131383 (1993).","journal-title":"Diabetes Care"},{"key":"22617_CR62","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2337\/dc11-1109","volume":"35","author":"RD Ting","year":"2012","unstructured":"Ting, R. D. et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 35, 218\u2013225 (2012).","journal-title":"Diabetes Care"},{"key":"22617_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.353","volume":"8","author":"J Li","year":"2017","unstructured":"Li, J. et al. FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway. Cell Death Dis. 8, e2965 (2017).","journal-title":"Cell Death Dis."},{"key":"22617_CR64","doi-asserted-by":"publisher","unstructured":"Price, N. L. et al. Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis. JCI Insight 4 https:\/\/doi.org\/10.1172\/jci.insight.131102 (2019).","DOI":"10.1172\/jci.insight.131102"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22617-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T22:47:52Z","timestamp":1724885272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22617-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22617"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22617-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739992371.793585330","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.29.178228","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2368"}}